Dr. Rajiv Bahl
Secretary, Department of Health Research, Ministry of Health & Family Welfare | Director General, ICMR
In the history of Indian biomedical research, few transitions have been as consequential as the one that occurred on 7 October 2022, when Dr. Rajiv Bahl — a physician-scientist forged across two decades of global public health work at the World Health Organization, Geneva — returned to lead the institution he had once served as a junior scientist: the Indian Council of Medical Research (ICMR). As both Secretary, Department of Health Research, Ministry of Health and Family Welfare, and Director General of ICMR, he now occupies the apex of India’s health research establishment — a dual role that places him at the intersection of science, policy, and national ambition.
FORMATION AND INTELLECTUAL GENEALOGY
Dr. Bahl’s intellectual formation is rooted in clinical medicine and rigorous quantitative science. He holds an MD in Paediatrics from the University of Delhi and a PhD from the All India Institute of Medical Sciences (AIIMS), New Delhi, where he trained his attention on the biological and epidemiological architecture of childhood illness. In 2022, the University of Bergen, Norway, conferred upon him an honorary doctorate — a recognition by one of the world’s leading institutions in global health of a career defined by scientific contributions that have moved far beyond the journal page into the fabric of child survival worldwide.
His early career, between 1994 and 2002, was spent as a scientist at the ICMR Advanced Centre for Diarrheal Disease and Nutrition Research at AIIMS. This foundational decade in the corridors of India’s most demanding research environment shaped his core competency: the design and execution of clinical science that is simultaneously rigorous, replicable, and policy-translatable.
TWO DECADES AT WHO
In 2003, Dr. Bahl joined the World Health Organization in Geneva, where he would spend the next nineteen years in an ascent that reflected both scientific credibility and administrative vision. From 2003 to 2012, he led WHO’s global programme on newborn and child health research, overseeing multi-country evidence generation that directly shaped the therapeutic protocols followed by paediatricians and community health workers across the developing world. From 2013 to 2022, his responsibility expanded to encompass Maternal, Newborn, Child and Adolescent Health research — a domain of the highest humanitarian stakes, encompassing billions of lives across Asia and Africa.
During this period, Dr. Bahl conducted and led research spanning more than 20 countries, and helped build scientific capacity in over 50 institutions globally. He was not merely a generator of evidence; he was an architect of research ecosystems in settings where the infrastructure for rigorous science had to be constructed from near-zero. His contributions to the evidence base on zinc supplementation in childhood diarrhoea, early initiation and exclusive breastfeeding, outpatient treatment of newborns with severe infections, and immediate Kangaroo Mother Care in intensive-care settings — taken together — are estimated to have the potential to save over one million lives annually worldwide if universally implemented.
Dr. Bahl has authored over 250 peer-reviewed papers, placing him among the most productive physician-scientists in Indian public health history. His h-index, reported in the range of 78–83 in official biographical sources, situates him in the highest tier of global biomedical researchers — a level of scholarly impact rarely achieved by scientist-administrators who simultaneously carry heavy institutional responsibilities. He is consistently identified in independent global assessments as among the most influential researchers in maternal and child health.
RETURNING TO LEAD
Since assuming charge of ICMR, Dr. Bahl has positioned the Council at the forefront of India’s vision of Viksit Bharat — a self-reliant, innovating India in which health research is not derivative of global north priorities but is generative, sovereign, and oriented toward Indian epidemiological realities. Under his leadership, ICMR has emphasised indigenous diagnostic development, med-tech translation, and the forging of stronger structural links between academic research, the pharmaceutical and medical devices industry, and national health programmes. He is the primary public voice for the Council’s scientific direction, frequently engaging with policymakers, principals, and scientific communities on the challenge of closing the distance between research evidence and programme implementation in India.
In one of his most candid recent statements, he described the transformation he envisions for ICMR not merely as an upgrade of infrastructure but as a radical cultural shift — toward a culture of accountability, translation, and measurable public health impact. For a Council that manages India’s largest network of biomedical research institutes, this is no small aspiration.
